凝血酶原复合物与冰冻血浆用于心脏手术凝血病性出血:FARES-II多中心随机临床试验
FARES-II是在加拿大和美国12家医院开展的非盲随机非劣效性试验,纳入心脏手术停止体外循环后发生凝血因子缺乏相关出血的成人患者。265例随机接受凝血酶原复合物(≤60 kg 1500 IU,>60 kg 2000 IU),263例接受冰冻血浆(≤60 kg 3 U,>60 kg 4 U)。主要分析纳入420例,凝血酶原复合物组止血有效率77.9%(166/213),冰冻血浆组60.4%(125/207),差异17.6%(95%CI 8.7%-26.4%),非劣效性和优效性均P<.001。凝血酶原复合物组输血量更少(平均6.6 U vs 9.3 U,差异2.7,95%CI 1.0-4.4,P=.002),严重不良事件更少(36.2% vs 47.3%,RR 0.76,95%CI 0.61-0.96,P=.02),急性肾损伤更少(10.3% vs 18.8%,RR 0.55,95%CI 0.34-0.89,P=.02)。
要点
- 心脏手术停止体外循环后凝血因子缺乏相关出血成人,凝血酶原复合物止血有效率77.9% vs 冰冻血浆60.4%,差异17.6%(95%CI 8.7%-26.4%)。
- 凝血酶原复合物组平均输血6.6 U(95%CI 5.7-7.7) vs 冰冻血浆组9.3 U(95%CI 8.0-10.8),差异2.7(95%CI 1.0-4.4,P=.002)。
- 严重不良事件:凝血酶原复合物组36.2% vs 冰冻血浆组47.3%,RR 0.76(95%CI 0.61-0.96,P=.02)。
- 急性肾损伤:凝血酶原复合物组10.3% vs 冰冻血浆组18.8%,RR 0.55(95%CI 0.34-0.89,P=.02)。
- 给药方案:凝血酶原复合物≤60 kg 1500 IU、>60 kg 2000 IU;冰冻血浆≤60 kg 3 U、>60 kg 4 U,均于手术室给药,24小时内可追加第二剂,其后仅可用冰冻血浆。
适用人群与场景
- 成人(≥18岁)心脏手术患者,在手术中停止体外循环后发生凝血因子缺乏相关出血。
- 研究在加拿大和美国的12家医院进行,随机化时间为2022年11月30日至2024年5月28日,最终30天随访于2024年6月28日完成。
处置流程与药物剂量
- 凝血酶原复合物组:体重≤60 kg给予1500 IU,体重>60 kg给予2000 IU,于手术室给药。
- 冰冻血浆组:体重≤60 kg给予3 U,体重>60 kg给予4 U,于手术室给药。
- 若有必要,24小时内允许给予第二剂;此后仅可使用冰冻血浆。
研究设计与关键结果
- 非盲随机非劣效性对照临床试验,12家医院,538例入组,420例纳入主要分析(中位年龄66岁,IQR 57-73岁;74%男性;10%亚洲人;1%黑人;65%白人),其中296例(70%)接受复杂手术。
- 主要终点止血有效(治疗开始后60分钟至24小时内未发生止血干预):凝血酶原复合物组166/213(77.9%) vs 冰冻血浆组125/207(60.4%),差异17.6%(95%CI 8.7%-26.4%),非劣效性和优效性P<.001。
- 输血量(包括红细胞、血小板和非研究用冰冻血浆单位):凝血酶原复合物组平均6.6 U(95%CI 5.7-7.7) vs 冰冻血浆组9.3 U(95%CI 8.0-10.8),差异2.7(95%CI 1.0-4.4,P=.002)。
- 严重不良事件:凝血酶原复合物组77/213(36.2%) vs 冰冻血浆组98/207(47.3%),RR 0.76(95%CI 0.61-0.96,P=.02)。
- 急性肾损伤:凝血酶原复合物组22/213(10.3%) vs 冰冻血浆组39/207(18.8%),RR 0.55(95%CI 0.34-0.89,P=.02)。
- 随访至术后第30天。
证据类型、等级与局限
- 证据类型:非盲随机非劣效性对照临床试验。
- 非劣效性界值10%,单侧α=.025;若证明非劣效则进一步检验优效性。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在接受凝血因子替代治疗的心脏手术出血患者中,凝血酶原复合物较冰冻血浆具有更优的止血疗效和安全性优势。
- 研究方案中凝血酶原复合物按体重给药(≤60 kg 1500 IU,>60 kg 2000 IU),24小时内可追加第二剂,其后仅可用冰冻血浆。
- 研究为非盲设计,主要分析纳入420/538例随机化患者。
指南或共识出处
- FARES-II多中心随机临床试验,ClinicalTrials.gov注册号NCT05523297。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Excessive bleeding is a common and prognostically important complication of cardiac surgery. For bleeding related to coagulation factor deficiency, frozen plasma is the most used therapy. Preliminary trials indicate that 4-factor prothrombin complex concentrate (PCC) may be a suitable alternative.
OBJECTIVE: To compare the efficacy and safety of PCC with frozen plasma in patients undergoing cardiac surgery with coagulopathic bleeding.
DESIGN, SETTING, AND PARTICIPANTS: Unblinded randomized noninferiority controlled clinical trial at 12 hospitals in Canada and the US involving adults (≥18 years) who had developed bleeding related to coagulation factor deficiency after termination of cardiopulmonary bypass during surgery (November 30, 2022, to May 28, 2024). Final 30-day follow-up visit was completed on June 28, 2024.
INTERVENTION: A total of 265 patients were randomized to receive PCC (1500 IU ≤60 kg; 2000 IU >60 kg) and 263, frozen plasma (3 U ≤60 kg; 4 U >60 kg) in the operating room. A second dose was allowed over the next 24 hours if indicated; thereafter, only frozen plasma could be used.
MAIN OUTCOMES AND MEASURES: The primary outcome was hemostatic response (effective if no hemostatic interventions occurred from 60 minutes to 24 hours after treatment initiation). The noninferiority of PCC vs frozen plasma was assessed using a 10% margin and a 1-sided α of .025, with subsequent testing for superiority if noninferiority was demonstrated. Secondary outcomes included allogeneic blood transfusions and adverse events. Patients were followed up until postoperative day 30.
RESULTS: Of 538 enrolled patients, 420 patients (median age, 66 years [IQR, 57-73 years]; 74%, male; 10%, Asian; 1%, Black; and 65%, White) were included in the primary analysis; of those, 296 (70%) underwent complex surgeries. Compared with the 207 patients in the frozen plasma group, the 213 patients in the PCC group had higher hemostatic effectiveness (166 [77.9%] vs 125 [60.4%]; difference, 17.6%; 95% CI, 8.7%-26.4%; P < .001 for noninferiority and superiority) and had received fewer transfusions including red blood cells, platelets, and noninvestigational frozen plasma units (mean, 6.6 units; 95% CI, 5.7-7.7 vs 9.3 units; 95% CI, 8.0-10.8; difference, 2.7; 95% CI, 1.0-4.4; P = .002). Seventy-seven patients (36.2%) in the PCC group vs 98 (47.3%) in the frozen plasma group experienced serious adverse events (relative risk [RR], 0.76; 95% CI, 0.61-0.96; P = .02). Twenty-two patients (10.3%) in the PCC group and 39 (18.8%) in the frozen plasma group had acute kidney injury (RR, 0.55; 95% CI, 0.34-0.89; P = .02).
CONCLUSIONS AND RELEVANCE: In this unblinded randomized clinical trial, PCC had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring coagulation factor replacement for bleeding during cardiac surgery.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05523297.
参考来源
- Karkouti K, Callum JL, Bartoszko J, et al. Prothrombin Complex Concentrate vs Frozen Plasma for Coagulopathic Bleeding in Cardiac Surgery: The FARES-II Multicenter Randomized Clinical Trial. JAMA. 2025. PMID: 40156829. doi:10.1001/jama.2025.3501
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。